
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
An antiretroviral regimen containing Viread, Videx, and Sustiva may be appealing because each medication is dosed just once daily, but the drug combination has a high failure rate, particularly among patients with high baseline HIV viral loads and low nadir CD4-cell counts, researchers reported at the Third International AIDS Society Conference on HIV Pathegenesis and Treatment. One-quarter of treatment-naive patients taking the regimen experienced virologic failure after 12 weeks of treatment; of them, 60% had a pre-treatment HIV viral load higher than 100,000 copies and a CD4-cell count below 200 cells. The National Institutes of Health in July recommended HIV caregivers to avoid giving an initial drug regimen containing Viread, Videx, and a nonnuke to treatment-naive patients because of the risk of treatment failure.
From our Sponsors
Most Popular
Plus: Featured Video